| Drug Type siRNA | 
| Synonyms RBD7007 | 
| Target | 
| Action inhibitors | 
| Mechanism C5 inhibitors(Complement C5 inhibitors) | 
| Therapeutic Areas | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Disorder of Complement | Phase 1 | China  | - | |
| Glomerulonephritis, IGA | Phase 1 | China  | - | |
| Hemoglobinuria, Paroxysmal | IND Approval | Sweden  | 01 Oct 2024 | |
| Rare Diseases | Discovery | China  | - | 





